Oncology
Lung Cancer
China sees 828,000 new cases and 715,000 deaths annually. 80% are non-small cell lung cancer (NSCLC), with 75% diagnosed in middle to late stages. Precise companion diagnostics are critical for treatment selection.
Digital PCR Solution
Multigene Companion Diagnosis
Aperbio's droplet chip digital PCR enables precise detection of key driver mutations to guide targeted therapy decisions.
- EGFR mutation (exon 18/19/20/21) — most common driver in Asian NSCLC
- KRAS G12/G13 mutations — resistance marker for EGFR therapy
- BRAF V600E — targetable in ~2% of NSCLC
- NRAS mutations — resistance monitoring
- ALK, HER2, NTRK, ROS1 fusion detection
Step-by-Step Process
1. Extraction
Automated nucleic acid extraction from liquid biopsy (ctDNA) or tissue samples.
2. Loading
Automated droplet chip loading with the Naica System — no manual partitioning needed.
3. Amplification & Analysis
Crystal Digital PCRâ„¢ with 6-color multiplexing and absolute quantification results.
Ready to Learn More?
Talk to our clinical application specialists about implementing lung cancer companion diagnostics in your lab.
Request a Demo